The COVID‐19 pandemic has not changed stage at presentation nor treatment patterns of head and neck cancer: A retrospective cohort study

Abstract

AbstractObjectivesTo evaluate the impact of the COVID‐19 lockdown measures on HNC, by comparing the stage at presentation and treatment of HNC before and after the most severe COVID‐19 restrictions.DesignA retrospective cohort study.SettingA regional cancer network serving a patient population of 2.4 million.ParticipantsNewly diagnosed patients with HNC between June and October 2019 (pre‐pandemic) and June and October 2021 (post‐pandemic).Main outcome measuresSymptom duration before diagnosis, stage at diagnosis, patient performance status (PS) and intent of treatment delivered (palliative vs. curative).ResultsFive hundred forty‐five patients were evaluated—250 in the 2019 and 295 in the 2021 cohort. There were no significant differences in symptom duration between the cohorts (p = .359) or patient PS (p = .821). There were no increased odds of presenting with a late (Stage III or IV) AJCC cancer stage in 2021 compared with 2019 (odds ratio [OR] = 0.90; 95% confidence interval [CI]: 0.76–1.08); nor increased odds of receiving palliative rather than curative treatment in 2021 compared with 2019 (OR = 0.68; 95% CI: 0.45–1.03).ConclusionThe predicted stage shift to more advanced disease at the time of diagnosis of HNC due to the COVID‐19 pandemic has not been realised in the longer term. In keeping with this, there was no difference in symptom duration, patient PS, or treatment patterns between the 2019 and 2021 cohorts.